These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 21816953)

  • 1. Application of homology modeling to generate CYP1A1 mutants with enhanced activation of the cancer chemotherapeutic prodrug dacarbazine.
    Lewis BC; Mackenzie PI; Miners JO
    Mol Pharmacol; 2011 Nov; 80(5):879-88. PubMed ID: 21816953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation, validation, and application of a P450 homology model.
    Lewis BC; Miners JO
    Curr Top Med Chem; 2013; 13(18):2233-40. PubMed ID: 24047137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1.
    Reid JM; Kuffel MJ; Miller JK; Rios R; Ames MM
    Clin Cancer Res; 1999 Aug; 5(8):2192-7. PubMed ID: 10473105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired dacarbazine activation and 7-ethoxyresorufin deethylation in vitro by polymorphic variants of CYP1A1 and CYP1A2: implications for cancer therapy.
    Lewis BC; Korprasertthaworn P; Miners JO
    Pharmacogenet Genomics; 2016 Oct; 26(10):453-61. PubMed ID: 27428168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of cytochrome P450 isoenzymes in metabolism of O(6)-benzylguanine: implications for dacarbazine activation.
    Long L; Dolan ME
    Clin Cancer Res; 2001 Dec; 7(12):4239-44. PubMed ID: 11751525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
    Roy P; Waxman DJ
    Toxicol In Vitro; 2006 Mar; 20(2):176-86. PubMed ID: 16293390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.
    Patterson LH; McKeown SR; Robson T; Gallagher R; Raleigh SM; Orr S
    Anticancer Drug Des; 1999 Dec; 14(6):473-86. PubMed ID: 10834269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human CYP1A1 variants lead to differential eicosapentaenoic acid metabolite patterns.
    Schwarz D; Kisselev P; Chernogolov A; Schunck WH; Roots I
    Biochem Biophys Res Commun; 2005 Oct; 336(3):779-83. PubMed ID: 16153604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative homology modeling of human cytochrome P4501A1 (CYP1A1) and confirmation of residues involved in 7-ethoxyresorufin O-deethylation by site-directed mutagenesis and enzyme kinetic analysis.
    Lewis BC; Mackenzie PI; Miners JO
    Arch Biochem Biophys; 2007 Dec; 468(1):58-69. PubMed ID: 17959138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of reciprocal active site mutations in human cytochromes P450 1A1 and 1A2 on alkoxyresorufin metabolism.
    Liu J; Ericksen SS; Sivaneri M; Besspiata D; Fisher CW; Szklarz GD
    Arch Biochem Biophys; 2004 Apr; 424(1):33-43. PubMed ID: 15019834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954.
    Grove JI; Lovering AL; Guise C; Race PR; Wrighton CJ; White SA; Hyde EI; Searle PF
    Cancer Res; 2003 Sep; 63(17):5532-7. PubMed ID: 14500391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of dacarbazine in the regional perfusion of extremities with melanoma.
    Didolkar MS; Jackson AJ; Lesko LJ; Fitzpatrick JL; Buda BS; Johnston GS; Zech LA
    J Surg Oncol; 1996 Nov; 63(3):148-58. PubMed ID: 8944058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained P450 expression and prodrug activation in bolus cyclophosphamide-treated cultured tumor cells. Impact of prodrug schedule on P450 gene-directed enzyme prodrug therapy.
    Schwartz PS; Chen CS; Waxman DJ
    Cancer Gene Ther; 2003 Aug; 10(8):571-82. PubMed ID: 12872138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxidative metabolism of the alkaloid rutaecarpine by human cytochrome P450.
    Ueng YF; Don MJ; Jan WC; Wang SY; Ho LK; Chen CF
    Drug Metab Dispos; 2006 May; 34(5):821-7. PubMed ID: 16501007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation.
    Mani C; Gelboin HV; Park SS; Pearce R; Parkinson A; Kupfer D
    Drug Metab Dispos; 1993; 21(4):645-56. PubMed ID: 8104124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations induced by dacarbazine activated with cytochrome P-450.
    Mudipalli A; Nadadur SS; Maccubbin AE; Gurtoo HL
    Mutat Res; 1995 Mar; 327(1-2):113-20. PubMed ID: 7532787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. cDNA cloning and characterization of feline CYP1A1 and CYP1A2.
    Tanaka N; Miyasho T; Shinkyo R; Sakaki T; Yokota H
    Life Sci; 2006 Nov; 79(26):2463-73. PubMed ID: 17097115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction, expression, and activities of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation.
    Siemers NO; Kerr DE; Yarnold S; Stebbins MR; Vrudhula VM; Hellström I; Hellström KE; Senter PD
    Bioconjug Chem; 1997; 8(4):510-9. PubMed ID: 9258449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of CYP1A1 polymorphisms with differential metabolic activation of 17beta-estradiol and estrone.
    Kisselev P; Schunck WH; Roots I; Schwarz D
    Cancer Res; 2005 Apr; 65(7):2972-8. PubMed ID: 15805301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homology modeling and molecular dynamics of CYP1A1 and CYP2B1 to explore the metabolism of aryl derivatives by docking and experimental assays.
    Rosales-Hernández MC; Mendieta-Wejebe JE; Trujillo-Ferrara JG; Correa-Basurto J
    Eur J Med Chem; 2010 Nov; 45(11):4845-55. PubMed ID: 20813430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.